Importantly, inhibition of the CD47 pathway with CD47 antibodies or other agents preferentially targeted tumor cells of both hematological and solid tumors rather than normal cells [14,17] suggesting that there is a “therapeutic window” for CD47-targeting therapeutics and that there are differences between cancer and normal cells in CD47-dependent signaling. This evidence concerns the gene CD47 and neoplasm.